Chimeric Therapeutics (Australia) Insiders

Chimeric Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.4871) % which means that it has lost $0.4871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8009) %, meaning that it generated substantial loss on money invested by shareholders. Chimeric Therapeutics' management efficiency ratios could be used to measure how well Chimeric Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Chimeric Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 5.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.1 M in 2025. Common Stock Shares Outstanding is likely to drop to about 474.6 M in 2025. Net Loss is likely to drop to about (11.8 M) in 2025

Chimeric Therapeutics Workforce Comparison

Chimeric Therapeutics Benchmark Summation

Chimeric Therapeutics Notable Stakeholders

The success or failure of an entity such as Chimeric Therapeutics often depends on how effective the management is. Chimeric Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chimeric management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chimeric management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Chimeric Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chimeric Therapeutics. Check Chimeric Therapeutics' Beneish M Score to see the likelihood of Chimeric Therapeutics' management manipulating its earnings.

When running Chimeric Therapeutics' price analysis, check to measure Chimeric Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimeric Therapeutics is operating at the current time. Most of Chimeric Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chimeric Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimeric Therapeutics' price. Additionally, you may evaluate how the addition of Chimeric Therapeutics to your portfolios can decrease your overall portfolio volatility.